Pfizer will pay $340m upfront and up to an additional $470m in milestone payments to purchase its portfolio company Therachon, providing an exit to Inserm Transfert Initiative.
Therachon, a Switzerland-based biotechnology developer focused on rare genetic disorders backed by medical research institute Inserm, yesterday agreed to an acquisition by pharmaceutical firm Pfizer for up to $810m.
Pfizer will pay $340m upfront and up to $470m in additional milestone payments related to the development of Therachon’s lead asset, TA-46, a treatment for a bone growth disorder called achondroplasia that causes disproportionate dwarfism.
Founded in 2014, Therachon is developing therapies for rare genetic diseases such as achondroplasia,…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
